Cargando…

Attenuation of cold stress-induced exacerbation of cardiac and adipose tissue pathology and metabolic disorders in a rat model of metabolic syndrome by the glucocorticoid receptor antagonist RU486

OBJECTIVES: Chronic stress affects the central nervous system as well as endocrine, metabolic and immune systems. However, the effects of cold stress on cardiovascular and metabolic disorders in metabolic syndrome (MetS) have remained unclear. We recently characterized DahlS.Z-Lepr(fa)/Lepr(fa) (DS/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagasawa, K, Matsuura, N, Takeshita, Y, Ito, S, Sano, Y, Yamada, Y, Uchinaka, A, Murohara, T, Nagata, K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855259/ https://www.ncbi.nlm.nih.gov/pubmed/27110688 http://dx.doi.org/10.1038/nutd.2016.14

Ejemplares similares

Highly purified eicosapentaenoic acid ameliorates cardiac injury and adipose tissue inflammation in a rat model of metabolic syndrome
por: Ito, S., et al.
Publicado: (2016)

Effect of the glucocorticoid receptor antagonist RU486 on MK-801 induced behavioural sensitisation
por: Lefevre, Emilia M., et al.
Publicado: (2017)

Inhibition of glucocorticoid-induced alteration of vimentin by a glucocorticoid receptor antagonist RU486 in the organ-cultured rat lens
por: Xie, Guo-Li, et al.
Publicado: (2011)

Effects of mTOR inhibition on cardiac and adipose tissue pathology and glucose metabolism in rats with metabolic syndrome
por: Uchinaka, Ayako, et al.
Publicado: (2017)

Mifepristone (RU486) inhibits dietary lipid digestion by antagonizing the role of glucocorticoid receptor on lipase transcription
por: Ma, Peng, et al.
Publicado: (2021)

RU486 did not exacerbate cytokine release in mice challenged with LPS nor in db/db mice
por: Yang, Baichun, et al.
Publicado: (2008)

The progesterone antagonist mifepristone/RU486 blocks the negative effect on life span caused by mating in female Drosophila
por: Landis, Gary N., et al.
Publicado: (2015)

Hepatocarcinogenic potential of the glucocorticoid antagonist RU486 in B6C3F1 mice: effect on apoptosis, expression of oncogenes and the tumor suppressor gene p53
por: Youssef, Jihan A, et al.
Publicado: (2003)

RU486 Mitigates Hippocampal Pathology Following Status Epilepticus
por: Wulsin, Aynara C., et al.
Publicado: (2016)

Anti-inflammatory effects of heat-killed Lactobacillus plantarum L-137 on cardiac and adipose tissue in rats with metabolic syndrome
por: Uchinaka, Ayako, et al.
Publicado: (2018)

Effects of RU486 in Treatment of Traumatic Stress-Induced Glucocorticoid Dysregulation and Fear-Related Abnormalities: Early versus Late Intervention
por: Lin, Chen-Cheng, et al.
Publicado: (2022)

Sex-related pharmacokinetic differences and mechanisms of metapristone (RU486 metabolite)
por: Chen, Wenge, et al.
Publicado: (2017)

Dietary Salt Restriction Improves Cardiac and Adipose Tissue Pathology Independently of Obesity in a Rat Model of Metabolic Syndrome
por: Hattori, Takuya, et al.
Publicado: (2014)

Novel RU486 (mifepristone) analogues with increased activity against Venezuelan Equine Encephalitis Virus but reduced progesterone receptor antagonistic activity
por: DeBono, Aaron, et al.
Publicado: (2019)

Mifepristone (RU-486) treatment for depression and psychosis: a review of the therapeutic implications
por: Gallagher, Peter, et al.
Publicado: (2006)

A study evaluating the effect of mifepristone (RU-486) for the treatment of leiomyomata uteri
por: Mukherjee, Sucheta, et al.
Publicado: (2011)

Tissue-specific alteration of gene expression and function by RU486 and the GeneSwitch system
por: Robles-Murguia, Maricela, et al.
Publicado: (2019)

The Impact of Mouse Preterm Birth Induction by RU-486 on Microglial Activation and Subsequent Hypomyelination
por: Morin, Cécile, et al.
Publicado: (2022)

Effects of P(4) Antagonist RU486 on VEGF and Its Receptors’ Signaling during the In Vivo Transition from the Preovulatory to Periovulatory Phase of Ovarian Follicles
por: Mauro, Annunziata, et al.
Publicado: (2021)

ROLES OF OXIDATIVE STRESS AND THE MINERALOCORTICOID RECEPTOR IN CARDIAC PATHOLOGY IN A RAT MODEL OF METABOLIC SYNDROME
por: TAKAHASHI, KEIJI, et al.
Publicado: (2015)

Determination of Mifepristone (RU-486) and Its Metabolites in Maternal Blood Sample after Pharmacological Abortion
por: Szpot, Paweł, et al.
Publicado: (2022)

A new role for RU486 (mifepristone): it protects sperm from premature capacitation during cryopreservation in buffalo
por: Dalal, Jasmer, et al.
Publicado: (2019)

Improved spatial memory, neurobehavioral outcomes, and neuroprotective effect after progesterone administration in ovariectomized rats with traumatic brain injury: Role of RU486 progesterone receptor antagonist
por: Amirkhosravi, Ladan, et al.
Publicado: (2021)

Effect of Antiprogesterone RU486 on VEGF Expression and Blood Vessel Remodeling on Ovarian Follicles before Ovulation
por: Mauro, Annunziata, et al.
Publicado: (2014)

SAT-486 A Unique Case of Pituitary Macroadenoma Unmasked by Glucocorticoid Treatment
por: Boddhula, Sowmya, et al.
Publicado: (2019)

Metapristone (RU486 metabolite) suppresses NSCLC by targeting EGFR-mediated PI3K/AKT pathway
por: Shao, Jingwei, et al.
Publicado: (2017)

Antiproliferative effect of mifepristone (RU486) on human neuroblastoma cells (SK-N-SH): in vitro and in vivo studies
por: Casulari, L.A., et al.
Publicado: (2020)

RU486 Metabolite Inhibits CCN1/Cyr61 Secretion by MDA-MB-231-Endothelial Adhesion
por: Yu, Suhong, et al.
Publicado: (2019)

Author Correction: A new role for RU486 (mifepristone): it protects sperm from premature capacitation during cryopreservation in buffalo
por: Dalal, Jasmer, et al.
Publicado: (2022)

SUN-739 Next Generation AR Antagonists Increase Systemic Active Glucocorticoid Exposure by Altering Glucocorticoid Metabolism
por: Alyamani, Mohammad, et al.
Publicado: (2020)

Pharmacoproteomic analysis reveals that metapristone (RU486 metabolite) intervenes E-cadherin and vimentin to realize cancer metastasis chemoprevention
por: Yu, Suhong, et al.
Publicado: (2016)

Characterization of a new animal model of metabolic syndrome: the DahlS.Z-Lepr(fa)/Lepr(fa) rat
por: Hattori, T, et al.
Publicado: (2011)

Mifepristone (RU-486(®)) as a Schedule IV Controlled Drug—Implications for a Misleading Drug Policy on Women’s Health Care
por: Hsieh, Yi-Ping, et al.
Publicado: (2022)

Demonstration of mixed properties of RU486 in progesterone receptor (PR)-transfected MDA-MB-231 cells: a model for studying the functions of progesterone analogues
por: Lin, V C-L, et al.
Publicado: (2001)

Twisted Gastrulation, a BMP Antagonist, Exacerbates Podocyte Injury
por: Yamada, Sachiko, et al.
Publicado: (2014)

GLUCOCORTICOID-INDUCED HYPERTENSION AND CARDIAC INJURY: EFFECTS OF MINERALOCORTICOID AND GLUCOCORTICOID RECEPTOR ANTAGONISM
por: HATTORI, TAKUYA, et al.
Publicado: (2013)

Fructose, Glucocorticoids and Adipose Tissue: Implications for the Metabolic Syndrome
por: Legeza, Balázs, et al.
Publicado: (2017)

Changes in the Transcriptome of the Human Endometrial Ishikawa Cancer Cell Line Induced by Estrogen, Progesterone, Tamoxifen, and Mifepristone (RU486) as Detected by RNA-Sequencing
por: Tamm-Rosenstein, Karin, et al.
Publicado: (2013)

Systems pharmacology of mifepristone (RU486) reveals its 47 hub targets and network: Comprehensive analysis and pharmacological focus on FAK-Src-Paxillin complex
por: Yu, Suhong, et al.
Publicado: (2015)

Metapristone (RU486-derivative) inhibits endometrial cancer cell progress through regulating miR-492/Klf5/Nrf1 axis
por: Chang, Yue, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4p1lahisnp8a0ge1v0tsd4i4hj